Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

125 results about "Reactogenicity" patented technology

In clinical trials, the term reactogenicity refers to the property of a vaccine of being able to produce common, "expected" adverse reactions, especially excessive immunological responses and associated signs and symptoms—fever, sore arm at injection site, etc. (Much less frequently, the term has also been applied to therapeutic drug trials.) Other manifestations of reactogenicity typically assessed in such trials include bruising, redness, induration, and swelling.

Preparation and use of giant panda Ascaris schroederi antigen

The invention discloses preparation and application of a giant panda Ascaris schroederi Mcintosh antigen, which belong to the giant panda Ascaris schroederi Mcintosh prevention, treatment and detection field. The method comprises the following steps: a Ascaris schroederi Mcintosh antigen gene primer is designed; total RNA of ascarids undergoes reverse transcription by the RT-PCR method to synthesize cDNA, and then the cDNA is taken as a template for PCR amplification of a target product; the purified target product is connected with a pMD18-T vector and then converted into DH5 alpha competent bacteria; positive recombinant clone is selected through flat screening and culture of the bacteria, and the antigen genes have a Bs-Ag1gene, a Bs-Ag2 gene and a Bs-Ag3 gene after culture and sequencing; and then recombinant plasmids which are accurately sequenced are converted into Escherichia coli BL21 competent cells for mass expression of proteins after construction of the recombinant plasmids, induction expression and purification of the recombinant proteins. After detection and immunologic tests of the product and ELISA detection and analysis of a test animal antibody IgG, the Bs-Ag1gene, the Bs-Ag2 gene and the Bs-Ag3 gene of the giant panda Ascaris schroederi Mcintosh antigen can be taken as candidate genes for preparing genetic engineering vaccines through the sascarids; and the recombinant proteins Bs-Ag1, Bs-Ag2 and Bs-Ag3 have good reactionogenicity and can be used for detecting infection of giant panda Ascaris by the ELISA method.
Owner:SICHUAN AGRI UNIV

Prokaryotic soluble expression method of VP3 gene of South African type 2 foot-and-mouth disease virus

The invention discloses a prokaryotic soluble expression method of VP3 gene of a South African type 2 foot-and-mouth disease virus. The method comprises the following steps: according to a gene sequence of the South African type 2 foot-and-mouth disease virus, directly coupling an SUMO solubilization expression tag coding gene to the upstream of a VP3 protein coding gene of FMDV SAT2; introducingsix His tag coding genes into the upstream of SUMO; then, according to escherichia coli codon tropism, optimizing the HisSUMO-SAT2-VP3 gene; recombining the gene to a PUC57 plasmid; taking a HisSUMO-SAT2-VP3-PUC57 plasmid as a template; designing a specific primer for amplifying the South African type 2 foot-and-mouth disease virus VP3 gene; carrying out PCR amplification, and carrying out enzymedigestion on a target fragment and an expression vector by using the same restriction enzyme; cloning a target gene into a pET32a (+) prokaryotic expression vector; constructing a recombinant plasmidpET32a-HisSUMO-VP3; transferring the recombinant plasmid into escherichia coli for expression; and purifying recombinant protein. According to the invention, the pET32a-HisSUMO-VP3 prokaryotic expression vector is successfully constructed, expression in the escherichia coli is achieved, the purified target protein has good reactogenicity, and a foundation is laid for subsequent assembly of a SouthAfrican type 2 foot-and-mouth disease virus subunit vaccine.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI

Fusion protein SUMO1-PLA2, and preparation method and medical use thereof

InactiveCN105542012AOvercoming low protein expressionSolving technical challenges of insoluble expressionHydrolasesMicrobiological testing/measurementInclusion bodiesChemistry
The invention provides a fusion protein SUMO1-PLA2, and a preparation method thereof. The invention also provides a medical use of the SUMO1 fusion protein to solve the technical problem of insoluble expression of PLA2 in Escherichia coli. The fusion protein SUMO1-PLA2 is efficiently prepared by using a pColdTF cold-induced expression vector. The defects of low PLA2 protein expression level, subsequent purifying inconvenience brought by existence of an expression product in an inclusion body form, and lower reactogenicity and immunogenicity of the expression product than soluble proteins in the prior art are overcome in the invention.
Owner:JILIN UNIV

Chromatographic method for separating and purifying high-purity porcine circovirus Cap proteins

The invention relates to a chromatographic method for separating and purifying high-purity porcine circovirus Cap proteins. The chromatographic method comprises the following steps: (S1) grinding and breaking insect cells expressing the porcine circovirus Cap proteins, extracting supernatant, and filtering by virtue of a filter membrane with a pore diameter of 0.45 micron, so as to obtain an original sample solution containing the porcine circovirus Cap proteins; (S2) carrying out weak anion exchange chromatography on the original sample solution, so as to obtain a first purified solution; (S3) carrying out strong cation exchange exchange chromatography on the first purified solution, so as to obtain a second purified solution; and (S4) carrying out gel filtration chromatography on the second purified solution, so as to obtain a high-purity porcine circovirus Cap protein solution. By virtue of the chromatographic method, DNA, pigments and host cell proteins in a rough original sample solution obtained from the insect cells expressing the porcine circovirus Cap proteins can be removed, and the porcine circovirus Cap proteins are greatly concentrated so as to obtain the high-purity and high-concentration porcine circovirus Cap proteins, so that the immunogenicity and reactogenicity of the Cap proteins are improved, and side effects are reduced.
Owner:WUHAN HUIYAN BIOTECH

E2 recombinant protein and application thereof

The invention provides an E2 recombinant protein. The E2 recombinant protein has an amino acid sequence of a sequence table SEQ.ID.No.1, and the E2 recombinant protein has a base sequence of a sequence table SEQ.ID.No.2. The invention also provides application to an indirect ELISA kit for detecting bovine viral diarrhea virus antibodies. The E2 recombinant protein provided by the invention has high accuracy, not only is the neutrality of the protein ensured, but also the trouble of high mutation rate is avoided, and the recombinant protein is more beneficial to the development of a BVDV antibody detection technology. The E2 recombinant protein uses a traditional protein prokaryotic expression technology, the cost is low, the expression quantity is large, and after the successfully expressed E2 recombinant protein is subjected to urea gradient renaturation, the West blot detection reactionogenicity is strong. The E2 recombinant protein is applied to the indirect ELISA kit for detectingbovine viral diarrhea virus antibodies, and an established BVDV antibody ELISA detection method is high in sensitivity and good in specificity, is more beneficial to popularization and application ingrass-roots farmers, and is more beneficial to purification of BVDV in cattle herds in China.
Owner:SHIHEZI UNIVERSITY

Recombinant S1 protein of novel mutant strain of porcine epidemic diarrhea virus and subunit vaccine of recombinant S1 protein

The invention discloses a recombinant S1 protein of a novel mutant strain of a porcine epidemic diarrhea virus and a subunit vaccine of the recombinant S1 protein. The protein is obtained by the steps of cloning a fusion gene fragment PE(delta III)-S1(m)-KDEL3 containing a KDEL3 gene sequence, a gene sequence of III-region-deleted pseudomonas aeruginosa exotoxin A and an S1(m) gene sequence to a baculovirus vector to obtain a recombinant vector; carrying out recombinant vector site specificity transposition on a seroconversion DH10Bac competent cell of the recombinant vector to obtain a recombinant bacmid; transfecting the recombinant bacmid to an Sf9 cell under the mediation of a liposome to obtain a recombinant Sf9 cell; expressing by using the recombinant Sf9 cell. According to the invention, a PE(delta III)-S1(m)-KDEL3 fusion protein is firstly expressed by using a baculovirus expression system on the basis of optimizing the predilection of a codon of mammalian with S1 genes, so that the recombinant baculovirus for efficiently and accurately expressing the fusion protein is obtained. Proved by IFA and Western blot, the recombinant baculovirus can be used for accurately expressing the fusion protein, and the fusion protein has favorable reactionogenicity.
Owner:NANJING AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products